Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Improving Insurance Coverage for RSV Vaccines
The panel discusses what’s needed for payers to activate early coverage for RSV vaccines in adults and how coverage has been since the approval of the 2 RSV vaccines.
EP: 1.Overview of RSV Patient Populations
EP: 2.Complications Associated with RSV Infections
EP: 3.The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV
EP: 4.RSV: Risk Factors and How It’s Spread
EP: 5.Diagnostic Practices for RSV
EP: 6.Increasing Awareness of RSV Vaccines in At-Risk Patients
EP: 7.Shared Decision-Making Practices in RSV
EP: 8.Financial and Clinical Benefits of RSV Immunization
EP: 9.The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59
EP: 10.Addressing Vaccine Fatigue
EP: 11.Identifying Patients Eligible for RSV Vaccine
EP: 12.Current and Potential Obstacles Related to Administering RSV Vaccines
Now Viewing
EP: 13.Improving Insurance Coverage for RSV Vaccines
EP: 14.Improving RSV Vaccination Rates and Addressing Misinformation
EP: 15.Key Takeaways on RSV Vaccination
Video content above is prompted by the following questions:
- With RSV season shifting earlier in the year and hospitalization rates increasing, what is needed for payers to activate early coverage for RSV vaccines in adults?
- How has the recommendation from the ACIP (Advisory Committee on Immunization Practices) impacted coverage of an RSV vaccine?
- How has coverage by insurance companies been since the approval (60+) of the 2 RSV vaccines?
- How can potential insurance coverage for RSV vaccines for those between 50-59 be optimized?
- How can potential insurance coverage for RSV vaccines for those between 50-59 be optimized?
Related Videos
Related Content
Infant RSV Hospitalization Rates Drop in First Season With Widespread Preventive Product Use
May 14th 2025Article
New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the importance of timely vaccination and nirsevimab administration.
Read More
